ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Inflammation-related signature for prognostic prediction, tumor immune, genomic heterogeneity, and drug choices in prostate cancer: Integrated analysis of bulk and single-cell RNA-sequencing

Zhu, Weian; Huang, Jiongduan; Wu, Jianjie; Wu, Chenglun; Ye, Fengxi; Li, Xiang*; Lai, Wenjie*南方医科大学; 中山大学
Heliyon2023-11DOI: 10.1016/j.heliyon.2023.e21174
15阅读
引用收藏
分享

摘要

Background: Prostate cancer (PCa) ranks as the second most prevalent malignancy among males on a global scale. Accumulating evidence suggests that inflammation has an intricate relationship with tumorigenesis, tumor progression and tumor immune microenvironment. However, the overall impact of inflammation-related genes on the clinical prognosis and tumor immunity in PCa remains unclear.Methods: Machine learning methods were utilized to construct and validate a signature using The Cancer Genome Atlas (TCGA) for training, while the Memorial Sloan Kettering Cancer Center (MSKCC) and GSE70769 cohorts for independent validation. The efficacy of the signature in predicting outcomes and its clinical utility were assessed through a series of investigations encompassing in vitro experiments, survival analysis, and nomogram development. The association between the signature and precision medicine was explored via tumor immunity, genomic heterogeneity, therapeutic response, and molecular docking analyses, using bulk and single-cell RNA-sequencing data.Results: We identified 7 inflammation-related genes with prognostic significance and developed an inflammation-related prognostic signature (IRPS) with 6 genes. Furthermore, we demonstrated that both the IRPS and a nomogram integrating risk score and pathologic T stage exhibited excellent predictive ability for the survival outcomes in PCa patients. Moreover, the IRPS was found to be significantly associated with the tumor immune, genomic heterogeneity, therapeutic response, and drug selection. Conclusion: IRPS can serve as a reliable predictor for PCa patients. The signature may provide clinicians with valuable information on the efficacy of therapy and help personalize treatment for PCa patients.

学科与关键词

关键词
Prostate cancerInflammationPrognostic signatureSingle -cell RNA-SequencingTumor immuneGenomic heterogeneityDrug choices
相关
加载中…
  • Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy
    Luo, Yong; Liu, Xiaopeng; Lin, Jingbo*; Zhong, Weide*; Chen, Qingbiao*Mathematical Biosciences and Engineering, 2022, 19(11): 11345-11366.
  • Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer
    Zhang, Guian; Luo, Yong; Dong, Weimin; Zhong, Weide*Computational and Mathematical Methods in Medicine, 2022, 2022: 8233840.被引 4
  • An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer
    Zhang, Guian; Luo, Yong*International Journal of General Medicine, 2021, 14: 9031-9049.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Heliyon
发表日期
2023-11
卷期
第 9 卷, 第 11 期
页码
e21174
DOI
10.1016/j.heliyon.2023.e21174
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82303906]; Basic and Applied Basic Research Foundation of Guangdong Province [2021A1515111210, 2023A1515010588]

作者

  • Z

    Zhu, Weian (第一作者)

    sun yat sen univ

  • H

    Huang, Jiongduan

    sun yat sen univ

查看全部 7 位作者收起作者
  • W

    Wu, Jianjie

    sun yat sen univ

  • W

    Wu, Chenglun

    sun yat sen univ

  • Y

    Ye, Fengxi

    sun yat sen univ

  • L

    Li, Xiang (通讯)

    southern med univ

  • L

    Lai, Wenjie (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417